Roche and Stago terminate 40-year partnership

Roche and Diagnostica Stago’s partnership to collaborate to market Stago’s products has been terminated, with the exception of distributions in Japan.

As of the end of 2011, Roche will stop selling Stago’s products, ending their long-term collaboration in the business of Laboratory Coagulation.

Bertrand Bonnot, COO of Stago, said: “We are convinced that, after almost 40 years of successful partnership, it is the right timing for both companies to follow independent paths. Nevertheless, both Stago and Roche are committed to work together to ensure a seamless transition in the coming years.”

However, Roche Diagnostics Japan will continue to distribute Stago’s portfolio within the Japanese market under a separate agreement.

Stago will instead sell its products directly or through other distribution channels.

Stago is an IVD company based in Paris, which develops and markets reagents and automated systems for the investigation of blood coagulation disorders, with a focus in haemostasis.

Switzerland-based Roche is a leader in research-based healthcare with strengths in pharmaceuticals and diagnostics.